Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

1 result

  • Topics : Population groups
  • Language : Français
  • Active substance : liraglutide
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
  • Diseases and conditions (1)
  • Plus ...
    • Endocrine system and metabolic diseases (1)
    • Plus ...
      • Diabetes mellitus (1)
    • Immune system diseases (1)
    • Plus ...
      • Autoimmune diseases (1)
  • Population groups (1)
  • Plus ...
    • Geriatrics (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
Date
  • Last five years (1)
Langue
  • Français (1)
Substance active
  • liraglutide (1)
More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 1 result

  • XULTOPHY (insuline degludec/liraglutide), antidiabétique

    Medicine - Posted on 26/8/2021
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
Uz4hEVLQnBmuVcsz